Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors. Phase 1/2 study of NGM707, an ILT2/ILT4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results